Submitted by dcc on Thu, 2022-06-16 09:52 Study Title: A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)CIRB: Adult CIRB - Late Phase EmphasisLead Group: ECOG-ACRINStatus: ActiveReview Status: Available to Open
